208 related articles for article (PubMed ID: 7784060)
1. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells.
Su L; Mukherjee AB; Mukherjee BB
Oncogene; 1995 Jun; 10(11):2163-9. PubMed ID: 7784060
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.
Chang PL; Cao M; Hicks P
Carcinogenesis; 2003 Nov; 24(11):1749-58. PubMed ID: 12919959
[TBL] [Abstract][Full Text] [Related]
3. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
Chang PL; Chambers AF
J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
[TBL] [Abstract][Full Text] [Related]
4. 1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate- induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells.
Chang PL; Prince CW
Cancer Res; 1993 May; 53(10 Suppl):2217-20. PubMed ID: 8485706
[TBL] [Abstract][Full Text] [Related]
5. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
[TBL] [Abstract][Full Text] [Related]
6. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
Gardner HA; Berse B; Senger DR
Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
Dhar A; Hu J; Reeves R; Resar LM; Colburn NH
Oncogene; 2004 May; 23(25):4466-76. PubMed ID: 15064752
[TBL] [Abstract][Full Text] [Related]
8. Antisense downregulation of a mouse mammary tumor virus activated protooncogene in mouse mammary tumor cells reverses the malignant phenotype.
Li YX; Papkoff J; Sarkar NH
Virology; 1999 Mar; 255(1):138-49. PubMed ID: 10049829
[TBL] [Abstract][Full Text] [Related]
9. Transfer by pro gene transfection of tumor promoter-sensitive phenotype to promotion-insensitive JB6 cells.
Colburn NH; Smith BM; Wendel EJ; Dowjat WK; Shimada T
Cancer Res; 1988 Mar; 48(5):1195-200. PubMed ID: 3342399
[TBL] [Abstract][Full Text] [Related]
10. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
Jansen AP; Colburn NH; Verma AK
Oncogene; 1999 Oct; 18(42):5806-13. PubMed ID: 10523861
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
[TBL] [Abstract][Full Text] [Related]
12. 1 alpha,25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells.
Chang PL; Prince CW
Cancer Res; 1991 Apr; 51(8):2144-50. PubMed ID: 2009532
[TBL] [Abstract][Full Text] [Related]
13. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells.
Cmarik JL; Li Y; Ogram SA; Min H; Reeves R; Colburn NH
Oncogene; 1998 Jul; 16(26):3387-96. PubMed ID: 9692546
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
Li JJ; Dong Z; Dawson MI; Colburn NH
Cancer Res; 1996 Feb; 56(3):483-9. PubMed ID: 8564958
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.
Senger DR; Perruzzi CA; Papadopoulos A
Anticancer Res; 1989; 9(5):1291-9. PubMed ID: 2686530
[TBL] [Abstract][Full Text] [Related]
16. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.
Shanmugam V; Chackalaparampil I; Kundu GC; Mukherjee AB; Mukherjee BB
Biochemistry; 1997 May; 36(19):5729-38. PubMed ID: 9153413
[TBL] [Abstract][Full Text] [Related]
17. Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.
El-Tanani MK; Jin D; Campbell FC; Johnston PG
Oncogene; 2010 Feb; 29(5):752-62. PubMed ID: 19901966
[TBL] [Abstract][Full Text] [Related]
18. Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line.
Ma L; Gauvillé C; Berthois Y; Millot G; Johnson GR; Calvo F
Oncogene; 1999 Nov; 18(47):6513-20. PubMed ID: 10597254
[TBL] [Abstract][Full Text] [Related]
19. Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein.
Chackalaparampil I; Peri A; Nemir M; Mckee MD; Lin PH; Mukherjee BB; Mukherjee AB
Oncogene; 1996 Apr; 12(7):1457-67. PubMed ID: 8622862
[TBL] [Abstract][Full Text] [Related]
20. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
